Kynurenic acid (KYNA) is a neuroprotective tryptophan metabolite produced via the kynurenine pathway, functioning as an endogenous antagonist of NMDA receptors and α7-nicotinic acetylcholine receptors, and as an agonist of the GPR35 receptor. KYNA represents the protective branch of Tryptophan catabolism, counterbalancing the neurotoxic effects of quinolinic acid and providing broad anti-excitotoxic, anti-inflammatory, and analgesic properties. Its production is regulated by tissue-specific kynurenine aminotransferases (KATs) and can be modulated by peripheral factors including gut microbiome composition, systemic inflammation, and metabolic state.
Imagine the kynurenine pathway as a railway junction where trains carrying kynurenine cargo must choose between two tracks. One track leads to a weapons factory (quinolinic acid production) that manufactures neurotoxic ammunition—excitatory shells that overstimulate brain cells until they burn out. The other track leads to a fire-suppression station (KYNA production) that manufactures foam to dampen those fires before they spread.
The station master switching the tracks is inflammation: when inflammatory cytokines activate Microglia, they redirect most trains toward the weapons factory. But certain signals—like Butyrate from the gut, or muscle-derived factors during Exercise—can flip the switch back toward the fire-suppression station. KYNA itself acts like fireproof foam sprayed over NMDA receptors (the receptors that respond to glutamate's excitatory signals), blocking the glycine co-factor binding site so glutamate can't overstimulate neurons. It also activates a separate alarm system (GPR35) that tells immune cells to stand down. The foam can't cross the blood-brain barrier easily on its own—it needs to hitch a ride on the same transporter that carries other large amino acids—so most KYNA production happens locally in the brain when conditions are right, though peripheral KYNA can signal systemically.
graph TD
A[Tryptophan] -->|IDO/TDO| B[N-formylkynurenine]
B --> C[Kynurenine]
C -->|KAT I-IV| D[KYNA]
C -->|Kynurenine 3-monooxygenase| E[3-Hydroxykynurenine]
E --> F[Quinolinic Acid]
G[Inflammatory Cytokines] -->|Upregulate| H[Kynurenine monooxygenase]
H -.Shifts pathway toward.-> F
I[Butyrate/SCFAs] -->|Upregulate| J[KAT expression]
J -.Shifts pathway toward.-> D
D -->|Large neutral amino acid transporter| K[Crosses BBB]
style D fill:#90EE90
style F fill:#FFB6C6
Step 1: Tryptophan Catabolism Initiation
Step 2: Pathway Bifurcation
- kynurenine serves as branch point substrate
- Protective branch: kynurenine → KYNA via kynurenine aminotransferases (KAT I, II, III, IV)
- KAT I and III predominantly in periphery
- KAT II primarily in brain astrocytes
- Requires 2-Oxoglutarate (α-ketoglutarate) as co-substrate
- Neurotoxic branch: kynurenine → 3-Hydroxykynurenine → quinolinic acid
- Mediated by kynurenine 3-monooxygenase (KMO) in activated Microglia
Step 3: Receptor Interactions
KYNA acts at multiple targets with IC50 values:
-
NMDA receptor antagonism (IC50 ~7-15 μM at glycine site)
- Competitive antagonist at glycine co-agonist binding site (GluN1 subunit)
- Does NOT block glutamate binding site
- Reduces excitotoxicity without complete NMDA blockade
- Particularly effective against GluN2A/GluN2B-containing receptors
-
α7-nicotinic acetylcholine receptor antagonism (IC50 ~7 μM)
- Reduces cholinergic excitation
- Modulates dopamine release in striatum
- May contribute to cognitive effects at supraphysiological levels
-
GPR35 agonism (EC50 ~30-40 μM)
- G-protein coupled receptor activation
- Triggers Gαi/o signaling → reduced cAMP
- Induces β-arrestin recruitment → anti-inflammatory signaling
- Expressed on immune cells, neurons, and Enterocytes
Step 4: Blood-Brain Barrier Transport
- KYNA transported via large neutral amino acid transporter (LAT1/SLC7A5)
- Competes with other aromatic amino acids (Tryptophan, Tyrosine, Phenylalanine)
- Net brain uptake ~2-3% of peripheral KYNA under normal conditions
- Most brain KYNA produced locally by astrocytes
Inflammation-driven shift toward quinolinic acid:
- IFN-γ → upregulates IDO and KMO in Microglia
- TNF-α → enhances kynurenine monooxygenase activity
- IL-6 → sustains IDO expression
- TLR4 activation → preferentially activates neurotoxic branch
- Result: KYNA/quinolinic acid ratio decreases from ~4:1 to <1:1
Metabolic factors favoring KYNA:
- Butyrate → increases KAT II expression in astrocytes via HDAC inhibitor activity
- Short-chain fatty acids → enhance peripheral KYNA production
- PGC-1α from muscle exercise → induces skeletal muscle KAT expression
- Peripheral muscle KYNA production → reduces circulating kynurenine available for brain quinolinic acid synthesis
Neuropsychiatric Disorders:
- Depression: Reduced KYNA/kynurenine ratio correlates with symptom severity (ratio <0.3 in treatment-resistant cases vs >0.5 in healthy controls)
- Schizophrenia: Paradoxically shows elevated KYNA in some brain regions (dorsal striatum) but deficiency in others (hippocampus), creating regional imbalance
- Anxiety disorders: Low KYNA associated with heightened glutamatergic tone and fear conditioning
- Alzheimer's Disease: Progressive loss of astrocytic KYNA production as neuroinflammation advances
Pain Syndromes:
Neurodegenerative Conditions:
The shift away from KYNA production represents a manifestation of the Selfish Brain and selfish immune system competing for Tryptophan:
- Brain "wants" tryptophan for Serotonin synthesis (mood, sleep, appetite regulation)
- Immune system redirects tryptophan through kynurenine pathway during activation
- Initial shift toward KYNA is protective (reduces excitotoxicity during acute infection)
- Chronic inflammation depletes this protection, leaving brain vulnerable while immune system maintains tryptophan access
- Creates allostatic load: sustained immune-brain metabolic conflict
Shift Pathway Toward KYNA:
- Butyrate enhancement via dietary fiber (>30g/day) or supplementation (1-3g sodium butyrate)
- Exercise protocols: resistance training 3x/week increases muscle KAT activity within 4-6 weeks
- Specific probiotics: Lactobacillus plantarum PS128, Bifidobacterium infantis increase peripheral KYNA
- Anti-inflammatory strategies: reduce cytokines that drive KMO activity
Direct KYNA Modulation:
- Oral KYNA supplementation: poor bioavailability, limited BBB penetration
- KYNA prodrugs: under investigation for neuropsychiatric applications
- KMO inhibitors: experimental compounds shift balance toward KYNA by blocking quinolinic acid pathway
Biomarker Monitoring:
- Serum KYNA: normal range 30-60 nM (lab-dependent)
- KYNA/kynurenine ratio: >0.4 considered neuroprotective, <0.3 suggests pathway dysfunction
- Kynurenine/tryptophan ratio: >30 indicates excessive IDO activation
- Combined with CRP, IL-6 provides metabolic-inflammatory profile
Clinical Thresholds:
- KYNA <25 nM: high risk for excitotoxic vulnerability
- Kynurenine >2.5 μM: suggests chronic immune activation
- Quinolinic acid >300 nM: neurotoxic threshold in CNS
- KYNA/quinolinic acid ratio <1.5: loss of neuroprotection
¶ Evolutionary and Mismatch Perspective
The kynurenine pathway evolved as acute infection defense: temporary tryptophan shunting starves pathogens while KYNA provides short-term neuroprotection. Modern chronic inflammation from metabolic syndrome, chronic stress, gut dysbiosis, and sedentary behavior creates sustained pathway activation without resolution, depleting KYNA reserves and establishing chronic excitotoxic vulnerability—a clear Mismatch Disease pattern.
- KYNA blocks NMDA receptors at the glycine co-agonist site with IC50 of 7-15 μM, NOT the glutamate binding site
- Normal serum KYNA concentration: 30-60 nM; CSF levels typically 5-10 nM (brain produces most KYNA locally)
- KYNA/kynurenine ratio <0.3 associated with treatment-resistant depression and cognitive impairment
- Only 2-3% of peripheral KYNA crosses blood-brain barrier under physiological conditions
- Butyrate at 1-3 mM increases astrocytic KAT II expression 2-4 fold within 24-48 hours
- Exercise-induced PGC-1α increases skeletal muscle KYNA production 5-10 fold, reducing kynurenine available for brain quinolinic acid synthesis
- Inflammatory cytokines (IFN-γ, TNF-α) shift KYNA/quinolinic acid ratio from 4:1 to <1:1 within 24-72 hours
- KYNA activates GPR35 at EC50 of 30-40 μM, triggering anti-inflammatory signaling via β-arrestin
- Specific bacterial strains (Lactobacillus plantarum, certain Bifidobacterium species) can increase fecal and serum KYNA by 50-200%
- KAT II (astrocytic enzyme) requires 2-Oxoglutarate as co-substrate, linking KYNA production to Krebs cycle and energy metabolism
- α7-nicotinic receptor antagonism by KYNA at IC50 ~7 μM modulates dopamine release and may contribute to negative symptoms in Schizophrenia when KYNA is excessively elevated
- KYNA production shows circadian variation, peaking 2-4 hours after cortisol awakening response
- kynurenine pathway — KYNA is the protective branch product, opposing quinolinic acid neurotoxicity
- quinolinic acid — neurotoxic metabolite competing for kynurenine substrate; KYNA/quinolinic ratio determines net neuroprotection
- NMDA receptor — KYNA competitively antagonizes at glycine co-agonist site, reducing glutamate-mediated excitotoxicity
- GPR35 — G-protein coupled receptor activated by KYNA, mediating anti-inflammatory and analgesic effects
- Tryptophan — upstream precursor; tryptophan depletion reduces KYNA synthesis capacity
- neuroinflammation — inflammatory mediators shift pathway away from KYNA toward quinolinic acid production
- glutamate — primary excitatory neurotransmitter; KYNA reduces glutamatergic excitotoxicity without complete blockade
- blood-brain barrier — KYNA crosses via large neutral amino acid transporter (LAT1), competing with aromatic amino acids
- gut microbiome — specific bacterial strains (Lactobacillus plantarum, Bifidobacterium) enhance peripheral KYNA production
- IDO — initiates kynurenine pathway; upregulated by IFN-γ and inflammatory cytokines, driving kynurenine production
- Microglia — activated microglia preferentially produce quinolinic acid rather than KYNA via upregulated kynurenine monooxygenase
- depression — KYNA deficiency and elevated quinolinic acid contribute to glutamatergic dysfunction in depressive pathophysiology
- neuropathic pain — spinal KYNA deficiency removes tonic NMDA inhibition, enabling central sensitization and Secondary Hyperalgesia
- cytokines — IFN-γ, TNF-α, IL-6 shift pathway toward neurotoxic branch and suppress KAT activity
- chronic inflammation — sustained immune activation depletes neuroprotective KYNA while elevating neurotoxic quinolinic acid
- Butyrate — HDAC inhibitor that upregulates astrocytic KAT II expression, shifting pathway toward KYNA production
- cognitive decline — KYNA deficiency and elevated kynurenine/tryptophan ratio predict cognitive deterioration in aging and dementia
- TLR4 — activation by LPS or DAMPs preferentially drives neurotoxic branch, reducing KYNA/quinolinic acid ratio
- vagus nerve — vagal anti-inflammatory signaling may preserve KYNA production by reducing peripheral cytokine-driven IDO activation
- Exercise — induces muscle PGC-1α → increases skeletal muscle KAT → reduces circulating kynurenine available for brain quinolinic acid
- PGC-1α — transcriptional coactivator that upregulates KAT expression in skeletal muscle, creating peripheral kynurenine sink
- Short-chain fatty acids — SCFA including Butyrate enhance peripheral and central KYNA synthesis via histone modifications
- astrocytes — primary source of brain KYNA via KAT II; astrocytic dysfunction reduces neuroprotective capacity
- Lactobacillus plantarum — probiotic strain that significantly increases fecal and serum KYNA levels
- central sensitization — KYNA deficiency at spinal level removes glutamatergic brake, enabling pain amplification
- Schizophrenia — paradoxical regional KYNA imbalance (elevated in striatum, deficient in hippocampus) contributes to symptomatology
- 2-Oxoglutarate — essential co-substrate for KAT enzymes; links KYNA production to mitochondrial Krebs cycle function
- Serotonin — competes with kynurenine pathway for tryptophan substrate; inflammation-driven IDO reduces serotonin synthesis
- Multiple Sclerosis — microglial activation shifts toward quinolinic acid, depleting KYNA and exacerbating demyelination
- Alzheimer's Disease — progressive astrocytic dysfunction reduces KYNA production capacity as neuroinflammation advances
- Fibromyalgia — systemic KYNA depletion correlates with pain severity and cognitive dysfunction
- allostatic load — chronic KYNA depletion represents failed metabolic adaptation to sustained inflammatory stress